Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Acta Oncol. 2020 Mar;59(3):310-314. doi: 10.1080/0284186X.2019.1670862. Epub 2019 Sep 28.

Kalle E Mattila^{1

2}, Pia Vihinen^{1

2}, Susan Ramadan^{1

2}, Tanja Skyttä^{3

4}, Leena Tiainen^{3

4}, Meri-Sisko Vuoristo^{3

4}, Kristiina Tyynelä-Korhonen⁵, Jussi Koivunen⁶, Laura Kohtamäki⁷, Siru Mäkelä⁷, Micaela Hernberg⁷

¹ Fican West Cancer Centre, Department of Oncology and Radiotherapy, University of Turku, Turku, Finland.
² Turku University Hospital, Turku, Finland.
³ Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland.
⁴ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
⁵ Center of Oncology, Kuopio University Hospital, Kuopio, Finland.
⁶ Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.
⁷ HYKS Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

No abstract available

Publication types